Clinical trials: Acne
Acne Vulgaris
Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)
The purpose of this study is to evaluate the safety and efficacy of denifanstat compared with matching placebo in participants with moderate to severe acne vulgaris who are ≥12 years of age.
- Trial name
- NCT07863193
- Testing
- Denifanstat
- Where
- 23 sites in United States
- Volunteers
- 800 people
- Sponsor
- Sagimet Biosciences Inc.
Acne Vulgaris, Acne Vulgaris on the Face
Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne Vulgaris
This Phase III randomized, double-blind, placebo-controlled, adaptive, multicenter study evaluates the efficacy and safety of a new concentration of the fixed-dose combination EF190 in women with moderate acne vulgaris over six…
- Trial name
- PANDORA (NCT06905210)
- Testing
- Experimental drug (Cyproterone Acetate 2 mg and Ethinyl Estradiol 0.02 mg)
- Where
- 18 sites in Brazil
- Volunteers
- 531 people
- Sponsor
- Eurofarma Laboratorios S.A.
Acne
Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne
This is a 4-part study. Part A will be a randomized, double-blind, placebo-controlled investigation of single ascending doses (SAD) to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) biomarkers of…
- Trial name
- NCT06989840
- Testing
- TVB-3567
- Where
- 6 sites in United States, Australia
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Sagimet Biosciences Inc.
Acne
Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Participants With Acne Vulgaris
The objective of this study was to evaluate the efficacy, safety, and tolerability of a once daily topical application of IDP-121 Lotion compared with its vehicle (IDP-121 Vehicle Lotion) in participants with moderate to severe…
- Trial name
- NCT02932306
- Testing
- IDP-121 Lotion, IDP-121 Vehicle Lotion
- Where
- 39 sites in United States
- Volunteers
- 820 people
- Sponsor
- Bausch Health Americas, Inc.
Acne Vulgaris
Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Participants With Acne Vulgaris
study designed to assess the safety, tolerability, and efficacy of IDP-120 Gel and IDP-120 Vehicle Gel
- Trial name
- NCT03664752
- Testing
- IDP-120 Gel, IDP-120 Vehicle Gel
- Where
- 20 sites in United States, Canada
- Volunteers
- 585 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Hidradenitis Suppurativa (HS)
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label…
- Trial name
- TibuSHIELD (NCT06993610)
- Testing
- Tibulizumab Dose A, Tibulizumab Dose B
- Where
- 61 sites in United States, Canada and 4 more
- Volunteers
- 247 people
- Sponsor
- Zura Bio Inc
Acne Vulgaris
Study to Determine Efficacy, Safety, and Tolerability of B244 as a Topical Spray in Subjects With Moderate to Severe Acne Vulgaris
This is a phase 2b, randomized, double-blind, vehicle-controlled clinical trial evaluating the efficacy, safety, and tolerability of B244 compared to vehicle in the treatment of moderate to severe acne vulgaris in adolescents and…
- Trial name
- NCT07866105
- Testing
- B244, Vehicle
- Volunteers
- 176 people
- Sponsor
- AOBiome LLC
Acne-prone Skin, Skin Disease
Observational Assessment of Skin Appearance Changes During PRX S Cosmetic Treatment in Participants With Acne-Prone Skin
This pilot cohort study evaluates changes in skin surface appearance in adult participants with acne-prone skin during and following a standardized five-session course of PRX S (WiQo SpA), a topical cosmetic product designed for…
- Trial name
- NCT07866131
- Testing
- PRX S topical cosmetic treatment, WiQo home care regimen (Nourishing Cream; Balancing Cream)
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- WiQo S.p.A.
Acne Scars
Evaluation of Juläine (TM) for the Treatment of Atrophic Facial Acne Scars
This study aims to evaluate the effectiveness and safety of Juläine, an injectable medical device made of polylactic acid, for treating facial acne scars.
- Trial name
- NCT07058883
- Testing
- Juläine
- Where
- 2 sites in Poland
- Volunteers
- 55 people
- Sponsor
- Nordberg Medical AB
Acne Vulgaris
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
The aim of this study is to test the safety and efficacy of photodynamic therapy (PDT) for the medication Ameluz® performed with the PDT-lamp BF-RhodoLED® in comparison to the respective placebo treatment for moderate to severe…
- Trial name
- NCT05080764
- Testing
- 1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient), 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Biofrontera Inc.
Oily Skin, Acne Prone Skin
Dermal and Ophthalmological Acceptability and Comedogenicity Assessment of a Cosmetic Product
The goal of this clinical trial is to evaluate the dermatological and ophthalmological safety of a cosmetic product and to assess its comedogenic and acnegenic potential in participants with oily or acne-prone skin.
- Trial name
- NCT07848555
- Testing
- moisturizing cream
- Where
- Brazil
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Brainfarma Industria Química e Farmacêutica S/A
Acne
Safety of the Acne mRNA Vaccine in Adolescents 12 to 17 Years of Age With Moderate to Severe Acne
The purpose of this study is to assess the safety profile of intramuscular injections of the Acne mRNA vaccine at 3 dose levels compared with placebo in 12 to 17 years old participants with moderate to severe acne.
- Trial name
- NCT07756957
- Testing
- Acne mRNA (messenger ribonucleic acid) vaccine
- Volunteers
- 410 people
- Sponsor
- Sanofi
Acne, Acne Scars - Mixed Atrophic and Hypertrophic
AVAVA MIRIA General Use
A general protocol to treat a variety of dermatologic conditions and collect patient feedback. Primary outcome is the collection and analysis of patient questionnaires related to the overall experience of the device treatment.
- Conditions
- Acne, Acne Scars - Mixed Atrophic and Hypertrophic, Scars, Wrinkle
- Trial name
- NCT06868615
- Testing
- AVAVA
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- AVAVA, Inc.
Acne Vulgaris
Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris
The goal of this observational study is to learn about the effects of a treatment that contains clindamycin phosphate, adapalene, and benzoyl peroxide in people with acne.
- Trial name
- CHARM (NCT07205107)
- Testing
- clindamycin phosphate, adapalene and benzoyl peroxide
- Where
- 19 sites in Canada
- Volunteers
- 200 people
- Sponsor
- Bausch Health Americas, Inc.
Acne Vulgaris
Radiofrequency Treatment Versus Topical Therapy for Facial Acne Vulgaris
This clinical study will compare a radiofrequency (RF) treatment with a standard topical treatment for adults with mild-to-moderate inflammatory facial acne vulgaris.
- Trial name
- NCT07805655
- Testing
- Adapalene 0.1% and Benzoyl Peroxide 2.5% gel, Sequential Radiofrequency Treatment
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- Jeisys Medical Inc
Acne Vulgaris
A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris
The primary objective is to assess the efficacy of trifarotene 50 microgram per gram (mcg/g) cream versus vehicle cream when applied once daily (QD) for 12 weeks in Chinese participants with moderate facial and truncal acne…
- Trial name
- AKLIEF (NCT07186413)
- Testing
- Trifarotene, Vehicle Cream
- Where
- China
- Volunteers
- 561 people
- Sponsor
- Galderma R&D
Acne
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
The purpose of the trial is to evaluate the safety, efficacy and immunogenicity of up to 3 intramuscular injections of the Acne mRNA vaccine candidate at up to four dose levels in adult participants aged 18 to 45 years with…
- Trial name
- NCT06316297
- Testing
- Acne mRNA vaccine
- Where
- 94 sites in United States, Australia and 2 more
- Volunteers
- 800 people
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Acne Vulgaris
A Clinical In-Use Evaluation to Assess the Tolerability and Efficacy of a Moisturizer on Acne Prone Skin
The objective of this study is to evaluate the tolerance and efficacy of a facial moisturizer in subjects with mild to moderate acne vulgaris over a 4-week treatment period.
- Trial name
- NCT07224633
- Testing
- Use of Barrier Building Moisturizer
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Kenvue Brands LLC
Acne Vulgaris on the Face
Safety and Efficacy of Topical AT-004 1% in Participants With Acne Vulgaris (AV)
Double blinded, randomized, placebo-controlled trial to determine the safety and efficacy of topical AT-004 therapy in participants with acne vulgaris, including assessment of reduction in the number of acne lesions and IGA.
- Trial name
- NCT07774364
- Testing
- AT-004
- Where
- 3 sites in Denmark
- Volunteers
- 63 people
- Sponsor
- Arctic Therapeutics
Atrophic Acne Scars
ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars
Visit the study website https://dawnacnescarstudy.com/ACT for more information. Atrophic acne scars are flat, indented or with an inverted center scars that develop at the endpoint of the normal healing process for acne.
- Trial name
- NCT05995340
- Testing
- ELAPR002f Injectable Gel, Saline Active Control
- Where
- 12 sites in Canada, Germany
- Volunteers
- 157 people
- Sponsor
- AbbVie